Mirobálano

Myrobalan (Terminalia chebula Retz.): A Comprehensive Reference

1. Identity and Botanical Description

Nomenclature and Taxonomy

Myrobalan is the common English name for Terminalia chebula Retz., a traditional plant belonging to the genus Terminalia, family Combretaceae. It is native to India and Southeast Asia. Its full taxonomic classification places it in Kingdom Plantae; Division Magnoliophyta (flowering plants); Class Magnoliopsida (dicotyledons); Order Myrtales; Family Combretaceae (Indian almond family); Genus Terminalia L.; Species T. chebula (Gaertn.) Retz.

The standardized common English name is "chebulic myrobalan," with the Ayurvedic name haritaki and the Pinyin name he zi (for the fruit). Other less common names and synonyms used across cultures include Abhaya, Alalekaayi, Black Myrobalan, Chebulic Myrobalan, Halela, Har, Harre, Harad, Hezi, Ink Nut, Kadukki, Karakkaya, Myrobalan, Pathya, and Zhang–Qin–Ge, among others. Vernacular names also include, by region: shilikha (Assamese), haritaki (Bengali), hardi/harde (Gujarati), hara (Hindi), alale (Kannada), katukka (Malayalam), hirda (Marathi), halela (Persian), haritaki (Sanskrit), har (Sindhi), Kadukkai (Tamil), and Karaka (Telugu).

Botanical Description and Natural Range

Terminalia chebula, commonly called Black Myrobalan, is a tropical, deciduous tree with thick, black, and cracked bark, growing up to 30 m in height and 1 m in trunk diameter. It is native to South Asia, from India and Nepal east to southwest China, and south to Sri Lanka, Malaysia, and Vietnam.

T. chebula is found in the Sub-Himalayan tracks from Ravi eastwards to West Bengal and Assam, ascending up to altitudes of 1,500 m in the Himalayas. The leaves can be opposite or alternate, oval, and taper to the tip. The flowers, occurring in terminal spikes or short panicles, emit a strong, unpleasant odor and are yellow in color. The fruits are yellow to orange-brown and ovoid.

If unripe fruit is picked from the tree and dried, it becomes black in color and is called black myrobalan. The fruit is yellow when fully ripe. When the yellow fruit is dried, it becomes very hard and is known as yellow myrobalan. The tannin content of the fruit increases as it ripens, and the best myrobalan fruit for use in traditional medicine is described as stiff, heavy, free from decay, and sinking in water.

Common Forms and Preparations

In both Iranian traditional medicine and modern phytotherapy, the main medicinal part of myrobalan is the fruit. The fruit, seeds, bark, and leaves are also used in various remedies. The mode of administration in Iranian traditional medicine includes whole herb preparations for internal and external use. Either the dried powdered fruit or any of its extracts in water or alcohol are generally taken orally.

Terminalia chebula is a main ingredient in the Ayurvedic formulation known as Triphala. Triphala is a critical herbal blend in Ayurveda consisting of three medicinal fruits: Terminalia chebula Retz., Phyllanthus emblica Linn., and Terminalia belerica Retz. This formulation is used for its laxative, detoxifying, and rejuvenating effects.

2. Traditional and Historical Use

Ayurveda (India)

Harītakī has been one of the most common herbs used in Ayurvedic medicine from ancient times. It has a broad spectrum of action and has been available in traditional Indian households across all regions. Since Charaka's time, Indian physicians have extolled the virtues of haritaki or myrobalan, calling restoratives which include it by such names as "the unfailing," "the restorative," "the fearless against ill health," "the life-giving," and "the animating."

T. chebula has been extensively used in Ayurveda, Unani, and Homeopathic medicine. In both Ayurveda and Siddha medical systems, the fruits of T. chebula are employed in treating a diverse spectrum of health conditions, including chronic diarrhea, gastroenteritis, constipation, malabsorption syndrome, asthma, ulcers, dyspnea, dyspepsia, hemorrhoids, cough, candidiasis, hepatomegaly, urinary discharge, skin diseases, memory loss, epilepsy, cardiovascular diseases, diabetes, anorexia, as a hemostatic agent, and as a diuretic, antitussive, and wound healer.

T. chebula is called the "King of Medicine" in Tibet and is always listed at the top of the "Ayurvedic Materia Medica" because of its extraordinary power of healing. It is named Haritaki after harita, meaning green, and because it is sacred to Lord Shiva, known as "Hara," and grows in the Himalayas where Lord Shiva was thought to reside.

Traditional Chinese Medicine

Historically, the fruits of T. chebula have been used in China for over thousands of years, as documented in the Grasses and Trees in South China (Western Jin Dynasty, 266–317 AD), which describes it as a tall tree bearing green-yellow, oval-shaped fruits. Further historical references include the New Compilation of Materia Medica from the Tang Dynasty (618–907 AD), which notes its bitter flavor, warmth, and non-toxic nature, and notes that imports from India began during this period.

Chebulae Fructus (the dried fruit) is celebrated as the king of Tibetan medicines and is consistently named first in the Ayurvedic Materia Medica. In Chinese medicine, the fruits are characterized by bitter and sour flavors, neutral properties, and associations with the lung and large intestine meridians. The fruits are reputed to astringe the lungs and intestines, and benefit the throat, being prescribed for chronic diarrhea, persistent dysentery, ceaseless coughing, throat pain, voice loss, rectal prolapse, blood in the stool, and lung deficiency leading to wheezing and coughing.

Iranian Traditional Medicine

Terminalia chebula is widely used in the traditional medicine of India and Iran to treat diseases including dementia, constipation, and diabetes. This tree is known in Iranian traditional medicine (ITM) as halileh or halilaj, and the fruit is used to develop treatments. In ITM, it is described as an astringent with a "cold" and "dry" temperament.

Triphala: The Three-Fruit Formulation

Triphala is the equal mixture of three herbal fruits described in ancient Indian Ayurveda, written in Sanskrit during the 2nd century BC and compiled as the Charaka and Sushruta Samhita. The fruits are Haritaki (Terminalia chebula), Bibhitaki (Terminalia bellirica), and Amalaki (Emblica officinalis). This herbal preparation, Triphala, is used for the treatment of enlarged liver, stomach disorders, and pain in the eyes.

3. Key Constituents and Active Compounds

Overview of Phytochemistry

To date, studies have identified approximately 149 compounds within the plant, including tannins, phenolic acids, lignans, triterpenes, flavonoids, and volatiles. It is believed that tannins and phenolic acids are the principal bioactive constituents responsible for the majority of the pharmacological activities.

Hydrolysable Tannins

The main chemical constituents include hydrolysable tannins, which make up about one-third of the total chemical composition of the various bioactive metabolites found in the plant. The main chemical constituents include phenolic acids such as gallic acid, ellagic acid, and chebulic acid; gallotannins such as 1,6-di-O-galloyl-β-D-glucose; and ellagitannins such as punicalagin, casuarinin, and corilagin.

The tannin content of T. chebula amounts to 32–45% and includes gallic acid, ellagic acid, chebulic acid, chebulinic acid, punicalagin, and tannic acid. The fruit extract is known to contain several bioactive constituents such as chebulagic acid, chebulinic acid, gallic acid, ellagic acid, tannic acid, corilagin, polyphenolic compounds, triterpenoids, and ascorbate. Chebulagic acid and chebulinic acid are the major constituents.

Other Phenolic and Flavonoid Compounds

Other constituents include a coumarin conjugated with gallic acids called chebulin, as well as other phenolic compounds including ellagic acid, 2,4-chebulyl-β-D-glucopyranose, chebulinic acid, gallic acid, ethyl gallate, punicalagin, terflavin A, terchebin, luteolin, and tannic acid. The flavonoids quercetin, catechin, and kaempferol have also been detected.

Glycosides, Triterpenoids, and Other Constituents

A number of glycosides have been isolated from haritaki, including the triterpenes arjunglucoside I, arjungenin, and the chebulosides I and II. Monosaccharides and oligosaccharides (9%) detected include D-glucose, D-fructose, and saccharose. Fruit acids include quinic acid (1.5%), shikimic acid (2%), and fatty oil (from seeds; 40%).

Phytochemical studies have yielded over 149 identified compounds in various parts of Chebulae Fructus, including monoterpenes, sesquiterpenes, diterpenes, flavonoids, phenols, phenylpropanoids, diarylheptanoids, aromatics, fatty acids, polysaccharides, steroids, organic acids, alkaloids, and fatty alcohols. The main lignans in Chebulae Fructus include lithospermate B, terminaliate A, and termitomenin A.

Established Mechanisms of Action

Tannins such as casuarinin, chebulanin, and chebulinic acid have been reported to have significant antioxidant properties through the inhibition of lipid peroxidation and reduction of oxidative stress-mediated cellular damage. Terminalia chebula has been reported to have significant anti-inflammatory and anti-arthritic properties, mainly through the action of constituents like chebulagic acid and corilagin, which downregulate inflammatory responses and alleviate arthritis.

Gallic acid, chebulagic acid, corilagin, and chebulic acid are among the tannins responsible for the anti-inflammatory, antioxidant, antidiabetic, antimicrobial, anticarcinogenic, and anti-aging properties of T. chebula. Triterpenoids exhibit a range of biological activities including hypoglycemic, anti-tumor, antioxidant, hepatoprotective, antibacterial, renal, and immune system-regulating effects. These compounds demonstrate neuroprotective properties through various molecular mechanisms, including the modulation of neuroinflammation, oxidative stress, and autophagy. They may also mitigate neurological disorders by improving mitochondrial function and inhibiting endoplasmic reticulum stress.

Studies in cell culture have found that treatment with T. chebula extract significantly inhibited nuclear factor-κB (NF-κB) activity, a key transcription factor involved in inflammatory signaling.

4. Scientific Evidence by Area of Use

4.1 Antioxidant Activity

Antioxidant activity in Chebulae Fructus has been widely studied and CF has shown strong activity. The accumulation of reactive oxygen species (ROS) induces oxidative damage to DNA, oxidizes proteins, and leads to lipid peroxidation. This contributes to the development of numerous chronic conditions including cancer, diabetes mellitus, cardiovascular diseases, and atherosclerosis.

Results of one animal study showed that the antioxidant capacity of T. chebula was 6.85 times greater than that of the synthetic antioxidant butylated hydroxytoluene (BHT) in the DPPH radical-scavenging assay. Evidence note: This antioxidant activity is well documented in vitro and in animal models, but large-scale human clinical trials specifically targeting antioxidant endpoints are limited.

4.2 Antimicrobial and Anticaries Activity

Leaf and fruit extracts of T. chebula have demonstrated potent antibacterial activity against a number of gram-positive and gram-negative human pathogenic bacteria. It is rich in bioactive chemical constituents including hydrolysable tannins, chebulic acid, gallic acid, phenolics, flavonoids, and triterpenoids.

Oral health (human clinical evidence): A double-blind randomised controlled trial assessed the effectiveness of Terminalia chebula on plaque and gingival inflammation among undergraduate student volunteers who were randomly allocated into three groups: (1) T. chebula mouthwash (n = 30); (2) chlorhexidine 0.2% (active control, n = 30); and (3) distilled water (placebo, n = 30). Results showed that the T. chebula mouthrinse was as effective as chlorhexidine in reducing dental plaque and gingival inflammation. The study authors concluded that T. chebula may prove to be an effective mouthwash and that its extract can be used as an alternative to chlorhexidine mouthrinse with similar properties.

In a small clinical study, twenty high-caries-risk patients were asked to rinse with aqueous extract of T. chebula; salivary samples were collected for pH and microbial screening. There was a gradual increase in salivary pH up to 45 minutes post-rinse compared with pre-rinse values. T. chebula showed antimicrobial activity against S. mutans, Lactobacillus, and C. albicans strains, with optimal minimum inhibitory concentrations (MIC) at 50 µg/mL, 100 µg/mL, and 100 µg/mL respectively.

In laboratory studies, ethanol extract of T. chebula (EETC) treatment decreased insoluble glucan formation and downregulated the gene expression of glycosyltransferase B, C, and D and fructosyltransferase — key virulence factors of Streptococcus mutans. Evidence strength: The clinical evidence on oral health is promising but based on small trials. More rigorous and larger studies are needed for firm conclusions.

The specific mechanism of antibacterial activity and its efficacy in practical clinical applications need to be verified and confirmed by more in-depth scientific studies and clinical trials.

4.3 Gastrointestinal Effects

Chebulic myrobalan is used as a bowel regulatory tonic and gentle laxative in traditional Ayurvedic medicine. Reviewed literature indicates a distinctly spasmolytic character of plant extracts high in tannins, as well as tannin metabolites. The only opposing effect was found for T. chebula, which exhibited prokinetic activity. The majority of the results support the ethnopharmacological uses of tannins in gastrointestinal ailments accompanied by diarrhea.

Aqueous extracts of chebulic myrobalan (harar) were found to possess good anthelmintic activity, both separately and as a mixture in equal parts (locally known as Triphala) together with belleric myrobalan (bahera) and emblic myrobalan (amla).

Evidence strength: Gastrointestinal effects are among the most historically documented, but controlled human clinical trials focusing specifically on T. chebula as a standalone agent for these conditions remain limited. Most evidence comes from traditional use records, animal studies, and trials of Triphala (which includes two other fruits).

4.4 Analgesic and Anti-Inflammatory Activity

Human clinical evidence: A randomized, double-blind, placebo-controlled, crossover study enrolled twelve healthy male volunteers aged 18–40 years to evaluate the analgesic activity and safety of a single oral dose of 1,000 mg of T. chebula using a mechanical pain model. Twelve healthy volunteers were randomized to receive either a single oral dose of two capsules of T. chebula (500 mg each) or identical placebo capsules. T. chebula significantly increased pain threshold and pain tolerance compared to placebo; both study medications were well tolerated. The authors noted that further multiple-dose studies may be needed to establish analgesic efficacy in patients suffering from osteoarthritis, rheumatoid arthritis, and other painful conditions.

Evidence strength: This is a single small pilot study in healthy volunteers, not in patients with chronic pain conditions. Its results are preliminary; larger trials in clinical pain populations are required.

4.5 Antidiabetic Activity

T. chebula has been widely used in Ayurveda for the treatment of diabetes. The chloroform extract of T. chebula seed powder has been investigated for antidiabetic activity in streptozotocin-induced diabetic rats. The chloroform extract of T. chebula seeds produced dose-dependent reduction in blood glucose of diabetic rats comparable to that of the standard drug glibenclamide in short-term study.

T. chebula methanolic extract containing 2.7% chebulic acid was evaluated for its preventive effects against the formation of advanced glycation end products (AGEs). When tested against AGE formation and protein cross-linking by glycation, the extract showed inhibitory activity in a dose-dependent manner, and at a concentration of 1,000 µg/mL, presented activity similar to that of 5 mM aminoguanidine (a positive control).

In a rat model of type 2 diabetes, diabetic animals were treated with 500 and 1,000 mg/kg of aqueous extract of T. chebula fruits for six weeks. The extract showed anti-diabetic, anti-lipidemic, hepatoprotective, and renoprotective effects against diabetes mellitus, attributed to promotion of insulin release alongside the insulin-like action of its phytoconstituents.

Evidence strength: Antidiabetic evidence is largely preclinical — drawn from animal models and in vitro studies. There are no adequately powered human clinical trials demonstrating significant glycemic benefit from T. chebula as a sole intervention.

4.6 Cardiovascular and Cardioprotective Effects

Terminalia chebula holds strong antioxidant and anti-inflammatory potential that is correlated with its hepatoprotective, cardioprotective, and neuroprotective properties. It is renowned for its diverse phytochemical composition, which includes several bioactive compounds that contribute to its medicinal properties.

T. chebula is also documented as effective in the management of hypercholesterolemia, hypertension, and gastrointestinal motility. However, these statements derive from review literature synthesizing primarily preclinical data. Evidence strength: Cardioprotective effects are documented in animal models and cell-culture studies. Human clinical trials directly and exclusively testing T. chebula for cardiovascular endpoints are scarce.

4.7 Hepatoprotective Activity

The hepatoprotective qualities of T. chebula are widely recognized. A systematic review drawing from published literature up to 2023 via PubMed, Scopus, Cochrane database, and Google Scholar identified 115 studies in total, of which twelve met inclusion requirements. More in vivo and clinical studies for mechanism-based pharmacological evaluation are needed in the future to provide stronger scientific evidence for traditional uses.

4.8 Neuroprotective Activity and Cognitive Function

T. chebula is highly utilized in ethnic medicine, and its medicinal value is gradually being recognized, showing great potential in the improvement of mild cognitive impairment (MCI) disorders. Triterpenoid compounds demonstrate neuroprotective properties through various molecular mechanisms, including the modulation of neuroinflammation, oxidative stress, and autophagy. They may mitigate neurological disorders by improving mitochondrial function and inhibiting endoplasmic reticulum stress.

Evidence strength: Neuroprotective evidence is primarily from in vitro and animal studies, with very limited human trial data. This remains an early-stage area of research.

4.9 Anticancer Activity

Studies have demonstrated that the compounds found in Chebulae Fructus confer a broad spectrum of biological activities in vitro and in vivo, including anticancer properties, some of which are already integrated into clinical practice. Chebulagic acid isolated from T. chebula extract has been reported to inhibit cyclooxygenase and 5-lipoxygenase, key enzymes involved in inflammation and carcinogenesis.

Triphala (a combination of T. chebula, T. bellirica, P. emblica, and honey) has been evaluated for cytotoxic activity on HepG2, the human liver cancer cell line. All concentrations of the preparation, as well as cisplatin, were significantly effective against HepG2 cells; the IC₅₀ level for Triphala extract was 77.63 ± 4.3 µg/mL.

Evidence strength: Anticancer activity has been demonstrated in cell culture (in vitro) and animal models, and chiefly in the context of Triphala rather than isolated T. chebula. No clinical trials in cancer patients exist that attribute the anticancer effect to T. chebula alone.

4.10 Skin and Dermatological Use

T. chebula has shown antioxidant, anti-inflammatory, and tyrosinase enzyme inhibitory activities. A randomized, controlled, triple-blind clinical trial was designed to evaluate the efficacy of T. chebula 5% cream compared to hydroquinone 2% cream in treating patients with facial melasma (a multifactorial, acquired skin disorder of hyperpigmentation). The formulation of T. chebula 5% cream was prepared, and its stability and release studied. Participants were randomly assigned to receive T. chebula 5% cream or hydroquinone 2% cream at bedtime for 12 weeks.

Evidence strength: This trial addresses a specific dermatological application with a comparator arm, though full results require access to the publication. The tyrosinase inhibitory mechanism provides biological plausibility.

4.11 Antimicrobial Resistance Modification

A 2026 systematic review in Frontiers in Pharmacology addressed T. chebula as a resistance-modifying botanical drug against priority pathogens, noting its rich content of hydrolysable tannins, chebulic acid, gallic acid, phenolics, flavonoids, and triterpenoids. The review situates the plant in the growing context of antimicrobial resistance (AMR). Evidence strength: This area is primarily supported by in vitro data; translation to clinical settings requires further research.

5. Body Systems and Health Areas

The plant has been demonstrated to possess multiple pharmacological and medicinal activities, including antioxidant, antimicrobial, antidiabetic, hepatoprotective, anti-inflammatory, antimutagenic, antiproliferative, radioprotective, cardioprotective, antiarthritic, anticaries, gastrointestinal motility, and wound-healing activity. The body systems most associated with myrobalan based on the scientific and traditional record include:

• Gastrointestinal system: Laxative, bowel regulatory, antidiarrheal, anthelmintic, prokinetic, anti-ulcer activities.
• Oral and dental health: Anticaries, antiplaque, and anti-gingivitis activity (most clinical trial data exists here).
• Metabolic/endocrine system: Antidiabetic and anti-glycation properties (primarily preclinical).
• Cardiovascular system: Cardioprotective, antihypertensive, and lipid-lowering activities (primarily preclinical).
• Liver and kidneys: Hepatoprotective and nephroprotective properties (primarily animal models).
• Nervous system: Neuroprotective and potential cognitive support (primarily in vitro and animal data).
• Immune system: Immunomodulatory activity.
• Skin: Wound healing, anti-inflammatory, tyrosinase-inhibitory (depigmenting) activity.
• Infectious disease: Broad-spectrum antibacterial, antifungal, and antiviral activity.

6. Dosage Forms and Reported Dosages

The mode of administration includes whole herb preparations for internal and external use. Daily dosage in Iranian traditional medicine ranges from 3 to 9 g.

In the human analgesic crossover trial, the dose used was a single oral dose of 1,000 mg (administered as two capsules of 500 mg each).

In rat studies examining antidiabetic effects, the aqueous extract of T. chebula fruits was administered at doses of 500 and 1,000 mg/kg for six weeks. In another animal study, the blood glucose lowering activity of the chloroform extract was determined using doses of 100, 200, and 300 mg/kg in short-term study.

In a 28-day repeated-dose safety study, the No Observed Adverse Effect Level (NOAEL) was observed to be 1,000 mg/kg body weight.

Common supplement preparations available commercially include standardized fruit powder, standardized aqueous or hydroalcoholic extracts in capsule or tablet form, topical creams (the melasma trial used 5% cream), and mouthwash preparations (used in dental trials). Triphala, the classical compound formulation containing T. chebula, is widely available in powder, tablet, and liquid extract forms.

7. Safety Considerations and Interactions

Acute and Subacute Toxicity

A study on acute toxicity showed that the oral LD50 dose for myrobalan is greater than 2,000 mg/kg. Chronic administration to rats did not produce significant physiological changes when compared with control rats.

In vitro toxicity profiling at concentrations from 250–2,000 µg/mL assessed through cytotoxicity, hemolytic activity, mutagenicity, and genotoxicity assays revealed that T. chebula methanolic fruit extract exhibited neither cytotoxic nor genotoxic effect in PBMCs, nor hemolytic activity in red blood cells, and no mutagenic effect in Ames test strains. Acute and subacute toxicity studies showed no significant change in body weight, behavior, hematology, biochemical parameters, organ weight, or histopathology. Overall results of acute and subacute toxicity studies concluded that oral administration was relatively non-toxic.

In order to support the safety-in-use of the ethyl acetate-soluble portion of a T. chebula ethanol extract containing 29.4% chebulic acid content, the preparation was tested in an in vitro mutagenicity assay and single- and 14-day repeated-dose oral toxicity study. In the bacterial mutation assay, up to 5,000 µg/mL concentration, the numbers of colonies did not increase whether with or without metabolic activation.

Preclinical and Clinical Safety Profile

Terminalia chebula has a long history of use in traditional medicine, and both preclinical and clinical studies support its safety profile when used appropriately. Animal studies have generally demonstrated that extracts are well tolerated at therapeutic doses. Research involving acute and chronic toxicity tests typically shows no significant adverse effects at standard dosages, including evaluation of behavioral changes, organ function, and histopathological effects. Clinical trials involving human subjects have also provided evidence of T. chebula's safety.

In the human analgesic crossover trial, both study medications (1,000 mg T. chebula and placebo) were well tolerated.

Mutagenicity Assessment

Studies focusing on safety assessment have shown a safe appraisal for T. chebula. The mutagenicity and Ames test data add to the evidence base that the fruit extract, at standard concentrations, does not exhibit genotoxic activity.

Notable Interactions and Cautions

Despite substantial advancements, considerable gaps remain in understanding the complete mechanisms of action, pharmacokinetics, and safety profiles of its extracts and compounds. The following points are supported by the available literature:

• Antibiotic interaction (potential synergy): A systematic review classified T. chebula as a resistance-modifying botanical drug, and in vitro data shows that extracts can potentiate the activity of certain antibiotics including tetracycline, suggesting possible pharmacodynamic interaction when co-administered with antimicrobials.
• Blood glucose-lowering effects: The documented antidiabetic activity across multiple animal models and cell studies indicates a theoretical risk of additive hypoglycemia if co-administered with antidiabetic medications, though no human data are available to quantify this risk.
• High tannin content: The tannin content of the fruit increases as it ripens. The high tannin load characteristic of the fruit (up to 32–45% by some analyses) can affect mineral absorption and may interact with iron absorption if taken concomitantly with iron-containing foods or supplements. This is a class effect of tannin-rich botanicals.
• Pharmacokinetic gaps: Investigating the pharmacokinetic properties of chemical constituents in Chebulae Fructus extract is crucial for elucidating the metabolic pathways of drugs once introduced into biological systems, and given the intricate nature of the chemical compounds, it is essential to delineate how these substances integrate into the bloodstream to enhance understanding of their pharmacokinetic characteristics. Human pharmacokinetic data remain limited.

Overall Evidence Summary

Recent pharmacological studies have revealed that Chebulae Fructus extracts and isolated compounds possess a broad spectrum of biological activities, including antioxidant, anti-inflammatory, antiviral, anticancer, antibacterial, hepatoprotective, nephroprotective, neuroprotective, and anti-diabetic effects. Many of these properties have long been recognized in traditional folk medicine and subsequently evolved into important pharmaceutical treatments. However, for most therapeutic applications, the human clinical evidence base is limited to small pilots or, in most areas, to animal and in vitro studies. The strongest human-level evidence to date concerns oral health (dental plaque and gingivitis reduction). For systemic indications such as diabetes, cardiovascular protection, liver protection, and neuroprotection, the scientific literature is dominated by preclinical findings, and adequately powered randomized controlled trials are lacking. More in vivo and clinical studies for mechanism-based pharmacological evaluation should be conducted in the future to provide stronger scientific evidence for traditional uses.

References

• Comprehensive Review on Fruit of Terminalia chebula: Traditional Uses, Phytochemistry, Pharmacology, Toxicity, and Pharmacokinetics — PMC / Molecules 2024
• The Development of Terminalia chebula Retz. (Combretaceae) in Clinical Research — PMC / Journal of Advanced Pharmaceutical Technology & Research 2013
• Terminalia chebula Retz. as a Resistance-Modifying Botanical Drug against Priority Pathogens: A Systematic Review — Frontiers in Pharmacology 2026
• Potential Therapeutic Applications for Terminalia chebula in Iranian Traditional Medicine — Journal of Traditional Chinese Medicine 2016 (ScienceDirect)
• A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate Analgesic Activity of Terminalia chebula in Healthy Human Volunteers — PMC / Journal of Anaesthesiology Clinical Pharmacology 2016
• Comparative Evaluation of Terminalia chebula Extract Mouthwash and Chlorhexidine Mouthwash on Plaque and Gingival Inflammation — PubMed 2014
• Anti-Cariogenic Effect of Terminalia chebula — PMC 2014
• Antibacterial and Antioxidant Effect of Ethanol Extracts of Terminalia chebula on Streptococcus mutans — PMC / Clinical and Experimental Dental Research 2021
• Antidiabetic and Renoprotective Effects of the Chloroform Extract of Terminalia chebula Retz. Seeds in Streptozotocin-Induced Diabetic Rats — PMC / BMC Complementary and Alternative Medicine 2006
• Treatment with Terminalia chebula Extract Reduces Insulin Resistance, Hyperglycemia and Improves SIRT1 Expression in Type 2 Diabetic Rats — PMC 2023
• Inhibitory Effects of Terminalia chebula Extract on Glycation and Endothelial Cell Adhesion — PubMed 2011
• Terminalia chebula Retz. Fruit Extracts Inhibit Bacterial Triggers of Some Autoimmune Diseases and Potentiate the Activity of Tetracycline — PMC / Indian Journal of Microbiology 2018
• Effect of Extracts of Terminalia chebula on Proliferation of Keratinocytes and Fibroblast Cells — PMC 2014
• Proteomic Analysis of Terminalia chebula Extract-Dependent Changes in Human Lymphoblastic T Cell Protein Expression — PMC 2012
• Mutagenicity and Oral Toxicity Studies of Terminalia chebula — PubMed 2011
• Safety Assessment of Methanolic Extract of Terminalia chebula Fruit, Terminalia arjuna Bark and its Bioactive Constituent 7-Methyl Gallic Acid — PubMed / Regulatory Toxicology and Pharmacology 2018
• Oral Acute and Sub-Acute Toxic Effects of Hydroalcoholic Terminalia chebula and Achillea wilhelmsii Extracts in BALB/c Mice — PMC 2019
• The Potential of Terminalia chebula in Alleviating Mild Cognitive Impairment: A Review — PMC / Frontiers in Aging Neuroscience 2024
• Cardio-Protective Effects of Terminalia chebula: A Systematic Review — Journal of Heart Valve Disease 2024
• Phytochemical Profile and Pro-Healthy Properties of Terminalia chebula: A Comprehensive Review — International Journal of Food Properties 2023
• Assessment of the Cytotoxic Activity of Triphala on HepG2 Cancer Cell Line — PMC 2021
• Terminalia chebula — Overview, ScienceDirect Topics
• Terminalia chebula (Fruit) — AHPA Botanical Identity References Compendium
• Terminalia chebula — Wikipedia (for taxonomic and constituent summary)
• Hepatoprotective Activity of Haritaki (Terminalia chebula Retz): A Systematic Review — ResearchGate 2024